Newron Pharmaceuticals SPA

1 in Phase 3

Quick facts

Phase 3 pipeline

Safinamide (as add-on therapy) · Neurology
Safinamide is a monoamine oxidase B (MAO-B) inhibitor that also has a weak inhibitory effect on monoamine oxidase A (MAO-A).

Phase 2 pipeline

NW-3509a

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: